内容紹介
Examination of the Response Rate of Paclitaxel and Bevacizumab Therapy for Metastatic Advanced Breast Cancer According to the Lymphopenia Grade
Summary
Bevacizumab is a well-established anti-VEGF monoclonal antibody that inhibits angiogenesis. Herein, we examined the response rates according to the grade of lymphopenia in metastatic breast cancer patients treated with bevacizumab+paclitaxel therapy. The objective responses were evaluated according to the Response Evaluation Criteria in Solid Tumors(RECIST)Guideline v1.1. Toxicity was evaluated according to the Common Terminology Criteria for Adverse Events(CTCAE)v4.0. Twenty study patients were divided into group A(grade 2-4 lymphopenia)and group B(grade 1 lymphopenia or no decreased lymphocyte count)and compared. The mean progression-free survival(PFS)was 77.7 days in group A(n=7)and 56.8 days in group B(n=13). There was no significant difference between both groups(p=0.67, logrank test). The response rate(RR)was 14.3%(CR=0, PR=1, SD=3, PD=3)in group A, while in group B, it was 23.0%(CR=0, PR=3, SD=6, PD=4). Furthermore, the clinical benefit rate(CBR)was 57.1% in group A and 69.2% in group B.
要旨
bevacizumabは血管新生を阻害し抗腫瘍効果を発揮する抗VEGFモノクローナル抗体である。今回われわれは,bevacizumab使用中のリンパ球数の変動に注目し,奏効率との関連について検討を行った。当院においてpaclitaxel+bevacizumab併用療法治療を受けた進行・再発乳癌20例を対象とした。grade 2以上のリンパ球数減少を認めた群をA群,grade 1またはリンパ球数減少を認めなかった群をB群として両群の奏効率および無増悪生存期間(PFS)を比較した。A群7例,B群13例であり,PFSの平均値はA群77.7日,B群で56.8日と有意差は認めなかった(p=0.67,logrank)。奏効率はA群14.3%(CR 0例,PR 1例,SD 3例,PD 3例),B群23.0%(CR 0例,PR 3例,SD 6例,PD 4例)であり,臨床的有効率はA群57.1%,B群で69.2%とともにB群がA群を上回った。
目次
Summary
Bevacizumab is a well-established anti-VEGF monoclonal antibody that inhibits angiogenesis. Herein, we examined the response rates according to the grade of lymphopenia in metastatic breast cancer patients treated with bevacizumab+paclitaxel therapy. The objective responses were evaluated according to the Response Evaluation Criteria in Solid Tumors(RECIST)Guideline v1.1. Toxicity was evaluated according to the Common Terminology Criteria for Adverse Events(CTCAE)v4.0. Twenty study patients were divided into group A(grade 2-4 lymphopenia)and group B(grade 1 lymphopenia or no decreased lymphocyte count)and compared. The mean progression-free survival(PFS)was 77.7 days in group A(n=7)and 56.8 days in group B(n=13). There was no significant difference between both groups(p=0.67, logrank test). The response rate(RR)was 14.3%(CR=0, PR=1, SD=3, PD=3)in group A, while in group B, it was 23.0%(CR=0, PR=3, SD=6, PD=4). Furthermore, the clinical benefit rate(CBR)was 57.1% in group A and 69.2% in group B.
要旨
bevacizumabは血管新生を阻害し抗腫瘍効果を発揮する抗VEGFモノクローナル抗体である。今回われわれは,bevacizumab使用中のリンパ球数の変動に注目し,奏効率との関連について検討を行った。当院においてpaclitaxel+bevacizumab併用療法治療を受けた進行・再発乳癌20例を対象とした。grade 2以上のリンパ球数減少を認めた群をA群,grade 1またはリンパ球数減少を認めなかった群をB群として両群の奏効率および無増悪生存期間(PFS)を比較した。A群7例,B群13例であり,PFSの平均値はA群77.7日,B群で56.8日と有意差は認めなかった(p=0.67,logrank)。奏効率はA群14.3%(CR 0例,PR 1例,SD 3例,PD 3例),B群23.0%(CR 0例,PR 3例,SD 6例,PD 4例)であり,臨床的有効率はA群57.1%,B群で69.2%とともにB群がA群を上回った。